

AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning on page 7, line 22, as follows:

In a preferred embodiment of the present invention, the amino acid sequence of the glycopeptide comprises an N-terminal opioid message sequence, a C-terminal address sequence, and a linker sequence between the message sequence and the address sequence. A wide variety of opioid message sequences and address sequences are well-known and may be used in the present invention, in addition to non-opioid message sequences with the same address sequences. Suitable message sequences include the following:

Delta-Selective Message Sequences

Met-Enkephalin	Y-G-G-F-M (<u>SEQ ID NO: 1</u>)
DSLET	Y-dS-G-F-L-S
DTLET	Y-dT-G-F-L-T
DSTBULET	Y-dS(OtBu)-G-F-L-T
DPDPE	Y-dPen-G-F-dPen (SS)
Deltorphin	Y-dM-F-H-L-M-D-CONH ₂

Mu- and Kappa-Selective Message Sequences

Leu-Enkephalin	Y-G-G-F-L (<u>SEQ ID NO: 2</u>)
LYM-147	Y-dA-G-MeF
DAMGO	Y-dA-G-MeF-NH-CH ₂ CH ₂ OH
Dermorphin	Y-dA-F-G-Y-P-S
beta-Endorphin	Y-G-G-F-M-T-S-Q-T-P-L-V-T-T-L-F-K-N-A-I-I-K-N-A-Y-K- K-G-E (<u>SEQ ID NO: 3</u>)
alpha-neo-Endorphin	Y-G-G-F-L-R-K-Y (<u>SEQ ID NO: 4</u>)

beta-neo-Endorphin	Y-G-G-F-L-R-K-Y-P (<u>SEQ ID NO: 5</u>)
Peptide E	Y-G-G-F-M-R-R-V-G-R-P-E-W-W-M-D-Y-Q-K-R-Y-G-G-F-L (<u>SEQ ID NO: 6</u>)
Peptide F	G-G-E-V-L-G-K-R-Y-G-G-F-M (<u>SEQ ID NO: 7</u>)
Nociceptin (FQ)	F-G-G-F-L-R-R-I-R-P-K-L-K-W-N-N-Q (<u>SEQ ID NO: 8</u>)
Dynorphin A (1-17)	Y-G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q (<u>SEQ ID NO: 9</u>)
Dynorphin A (1-13)	Y-G-G-F-L-R-R-I-R-P-K-L-K (<u>SEQ ID NO: 10</u>)
Dynorphin B	Y-G-G-F-L-R-R-Q-F-K-V-V-T (<u>SEQ ID NO: 11</u>)
Morphiceptin	Y-P-F-P (<u>SEQ ID NO: 12</u>)
beta-Casomorphin	Y-P-F-P-G-P-I (<u>SEQ ID NO: 13</u>)
Endomorphin-1	Y-P-W-F (<u>SEQ ID NO: 14</u>)
Endomorphin-2	Y-P-F-F (<u>SEQ ID NO: 15</u>)
Rubiscolin-6	Y-P-L-D-L-F (<u>SEQ ID NO: 16</u>)

In the sequences listed above, dA, dS, dT, dM, dPen represent D-alanine, D-serine, D-threonine, D-methionine and D-penicilimine, respectively.

Please amend the paragraph beginning on page 9, line 14, as follows:

The glycopeptide may have the N-terminal sequence Y-a-G-F-, T-t-G-F-, Y-t-G-F-L-, Y-t-G-F-L-P-, Y-t-G-F-L- β A-, or Y-t-G-F-L-G-G-. The symbols “a”, “t” and “ β A” represent D-alanine, D-threonine and β -alanine, respectively. Unless noted otherwise, a single amino acid depicted in lower case refers to the D-amino acid. Other suitable N-terminal sequences include Y-G-G-, Y-G-G-F- (SEQ ID NO: 17), Y-m-F-, Y-m-F-H-, Y-a-F-, Y-a-F-G-, Y-P-F-, Y-P-F-P- (SEQ ID NO: 12), Y-P-F-F- (SEQ ID NO: 15), Y-P-W, and Y-P-W-F- (SEQ ID NO: 14). In addition, many non-opioid sequences may be used in the present invention,

including sequences from corticotropin releasing factor (CRF), lutenizing hormone (LH), human chorionogonadotropin (hCG), follicle stimulating hormone (FSH), vasoactive intestinal peptide (VIP), bradykinin, vasopressin, neurokinins, substance P, prolactin, and many other hypothalamic peptide hormones.

Please replace the originally filed Sequence Listing with the attached Substitute Sequence Listing beginning on new page 44.